Cancer drug demand drives higher sales for AstraZeneca
The drug-maker reported total revenues of 28 billion US dollars (£21 billion) for the first half of 2025.
This is 11% higher, at constant exchange rates, than the same period a year ago.
AstraZeneca said the uplift was largely driven by its oncology medicines, with product sales surging by 16% year on year, thanks to growth in demand for drugs including Tagrisso and Imfinzi.
Revenues from oncology products, which refer to the diagnosis and treatment of cancer, made up 43% of the company's total sales.
The group's pre-tax profit soared by 27% to 6.5 billion US dollars (£4.9 billion) for the first half, compared with last year.
AstraZeneca, which is based in the UK, last week pledged a mammoth investment into the US over the next five years, where it generates the highest proportion of sales.
The money will fund a new multibillion dollar manufacturing facility in Virginia, to be the firm's largest single manufacturing investment in the world.
The new factory will produce drug substances for its growing weight management and metabolic portfolio, including oral GLP-1 products.
GLP-1 is the scientific term for weight-loss medication, which works by reducing food cravings.
Oral medicines can be taken in tablet form, while other drugs are taken as injections.
'Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,' Pascal Soriot, AstraZeneca's chief executive, said.
'This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver 80 billion dollars revenue by 2030.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
18 minutes ago
- BBC News
BBC Sport secures multi-year rights deal to The AIG Women's Open
BBC Sport has signed a new multi-year agreement with The R&A, securing broadcast rights for The AIG Women's Open from 2025 to 2027. The deal guarantees free-to-air access for UK audiences, with coverage spanning radio commentary and coverage on Radio 5 Live, 5 Sports Extra and BBC Sounds, digital clips across the BBC Sport website, app, and social media platforms as well as TV highlights on BBC Two and iPlayer. The 2025 championship begins on Thursday 31 July at Royal Porthcawl, where BBC Sounds will provide full uninterrupted commentary from the first tee shot to the final putt on Sunday evening. Golf correspondent Iain Carter leads the commentary which can also be followed through the live pages of the BBC Sport website/app. Digital highlights will be available on the BBC Sport website/app and the BBC's social platforms. The TV highlights, presented by Sarah Mulkerrins, will showcase the best of the championship each day on BBC Two and iPlayer. Alex Kay-Jelski, Director of BBC Sport says, 'This deal is another great addition to BBC Sport's portfolio of women's sport. The Women's Open is a standout event in the golfing calendar, and we're bringing the action direct to audiences with coverage across TV, 5 Live and the BBC Sport website/app and socials. It's a chance to showcase not just a world-class competition, but the players and stories that make this event so compelling.' Mark Darbon, Chief Executive of The R&A, said, 'Millions of viewers will be able to enjoy the BBC's excellent coverage of the AIG Women's Open and watch and listen to the world's best women's players in action. We are delighted to be continuing our partnership with the BBC and to be working with them to promote women's golf to a wider audience.' The announcement follows last week's news that BBC Sport has also secured rights to broadcast The Open, reaffirming its long-standing commitment to showcasing the very best of golf to UK audiences. BBC Sport's summer of women's sport has been bigger than ever, featuring the Women's Rugby World Cup, UEFA Women's Euro 2025, Wimbledon, The Hundred, international women's cricket highlights, the World Athletics Championships. BBC Sounds (Sports Extra 3) Schedule: Thursday 31 July – 7am-7pm Friday 1 August – 7am-7pm Saturday 2 August – 11am-close of play Sunday 3 August – 11am-close of play CF Follow For More
BBC News
18 minutes ago
- BBC News
Cambridge driverless bus trial given £1m extra funding boost
An extra £1m has been secured to expand the operations of a city's driverless bus trial. launched in Cambridge in June and so far nearly 200 passengers have taken up the free travel. Greater Cambridge Partnership (GCP) has received the extra funds from the Centre for Connected and Autonomous Vehicles to extend trials of its 'Connector' project. Brian Milnes, chair of GCP's executive board, said the aim was to "make our public transport network more efficient, more inclusive, and better connected". "Securing this additional funding is a major vote of confidence in the work we're doing to shape the future of transport in Greater Cambridge," he added."We're not just trialling new vehicles, we're building the evidence base for a smarter, greener transport system that works for everyone." The current driverless bus trial runs from Madingley Road Park & Ride around the University of Cambridge's Eddington neighbourhood and into the Cambridge West Innovation offers four 18-minute loop services, which run in the mornings and afternoons, Monday to Friday, and has covered more than 700 miles (1,126km) so far, according to the also plans to trial self-driving passenger transport at the Cambridge Biomedical Campus. The additional investment means the trials will continue until at least next March. It will also fund an accessibility and inclusivity study to ensure the service meets the needs of all people, including disabled and older residents and parents of young children. The project is part of the Centre for Connected and Autonomous Vehicles' CAM Pathfinder Programme and has been funded by the has so far cost £7.8m, of which £5.3m is a government grant and this includes the latest £1m. Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X.
The Sun
18 minutes ago
- The Sun
Common medicines may not work for some people based on their DNA, experts find
A PILOT scheme has revealed a widespread genetic sensitivity to common medicines which could increase side effects or stop them working as they should. The trial saw 2,200 adults undergo whole genome sequencing to analyse how their individual DNA responds to the likes of antibiotics and over the counter painkillers. 1 A staggering 99 per cent showed a genetic variant that affects their sensitivity to certain medicines. This could mean some drugs, including over the counter, everyday painkillers, antibiotics and other prescription medications, won't work for some people based on their individual DNA. The blood test, part of Bupa's My Genomic Health scheme, also looked their genetic risk of developing 36 preventable diseases including cancers, heart conditions and type 2 diabetes. It found 91 per cent of participants were found to be at risk of developing a disease with genetic and lifestyle risk factors, such as fatty liver disease, breast cancer and certain heart diseases. While 73 per cent had multiple genetic variants that put them at raised risk of developing a condition that could be prevented or detected early, leading to better health outcomes, including the likes of high cholesterol, skin cancer and type 2 diabetes. And 49 per cent were found to be carriers of a genetic variant that could lead to raised risk of certain condition in future generations. Following the successful pilot, Medication Check can now be purchased through Bupa, and will also be available to more than three million its customers as part of its workplace health scheme. A saliva test will establish what medications are most likely to be effective, those with increased risk of adverse side effects, or ones that won't work for them at all. Dr Rebecca Rohrer, clinical innovation and genomics director for Bupa, said: 'We've long known that most medications only work for 30-50 per cent of the population. 'However, this pilot has highlighted just how significantly individual genomes impact the effectiveness of medications in treating conditions. Beware 3 of the most dangerous medicines in the world - including one found in almost EVERY home 'With more than half of us regularly taking a prescription medication and an increasing number affected by a chronic condition, it's crucial that people are prescribed the right medicine from the start, tailored to their unique genetic makeup. 'In the longer term, genomics is key to early detection and even preventing some illnesses altogether.' After completing the at-home medication check, patients will be offered a GP consultation with the healthcare provider to review any medication identified in their genetic tests. It comes as Bupa is about to introduce two new products to its My Genomic Health suite later this year, that will help to prevent or detect illness earlier. The DNA Health Check will give people early warning of an increased genetic risks of four different conditions - breast cancer, prostate cancer, type 2 diabetes and cardiovascular disease. While the Advanced DNA Health Check will combine insights from medication, disease risk, carrier status and traits, and will look at the genetic risk of developing conditions such as heart disease, metabolic disease and 10 types of cancer. Carlos Jaureguizar, CEO for Bupa Global, India & UK, said: 'Whole genomic sequencing is fundamentally changing our approach to healthcare, pivoting from treatment to prevention. 'It has the power to become a health passport that people can reference throughout their lives. 'We firmly believe genomics is the path to health innovation and prevention, reducing the nation's health burden and giving people personalised knowledge of their own genomic profile to live well for longer.'
